SGLT2抑制、胆碱代谢物与心血管代谢疾病:一项中介孟德尔随机化研究
采用两样本两步孟德尔随机化研究,发现SGLT2抑制(HbA1c每降低1个标准差,即6.75 mmol/mol [1.09%])与2型糖尿病和冠状动脉疾病风险降低相关,且与总胆碱、磷脂酰胆碱和甘氨酸水平升高相关。总胆碱和磷脂酰胆碱介导SGLT2抑制对2型糖尿病效应的8%和5%,甘氨酸介导对冠状动脉疾病效应的2%。
要点
- SGLT2抑制(HbA1c每降低1个标准差)与2型糖尿病风险降低相关(OR 0.25 [95%CI 0.12, 0.54])。
- SGLT2抑制与冠状动脉疾病风险降低相关(OR 0.51 [95%CI 0.28, 0.94])。
- 总胆碱和磷脂酰胆碱介导SGLT2抑制对2型糖尿病的效应,甘氨酸介导对冠状动脉疾病的效应。
核心结论
- 本研究识别了SGLT2抑制对胆碱代谢物的因果作用,SGLT2抑制可能通过不同胆碱代谢物影响2型糖尿病和冠状动脉疾病。
研究设计与样本
- 采用两样本两步孟德尔随机化研究,遗传代理为SLC5A2基因中与基因表达水平和糖化血红蛋白均相关的变异。
- 代谢物汇总数据来自UK Biobank,冠状动脉疾病数据来自CARDIoGRAMplusC4D联盟,2型糖尿病数据来自DIAGRAM和FinnGen研究。
主要发现
- SGLT2抑制(HbA1c每降低1个标准差,即6.75 mmol/mol [1.09%])与2型糖尿病风险降低相关(OR 0.25 [95%CI 0.12, 0.54]),与冠状动脉疾病风险降低相关(OR 0.51 [95%CI 0.28, 0.94])。
- SGLT2抑制与总胆碱(β 0.39 [95%CI 0.06, 0.72])、磷脂酰胆碱(β 0.40 [95%CI 0.13, 0.67])和甘氨酸(β 0.34 [95%CI 0.05, 0.63])水平升高相关。
- 总胆碱(OR 0.78 [95%CI 0.68, 0.89])和磷脂酰胆碱(OR 0.81 [95%CI 0.72, 0.91])与2型糖尿病相关,但与冠状动脉疾病不相关;甘氨酸与冠状动脉疾病相关(OR 0.94 [95%CI 0.91, 0.98]),但与2型糖尿病不相关。
- 中介分析显示,SGLT2抑制通过总胆碱(间接效应0.91 [95%CI 0.83, 0.99])和磷脂酰胆碱(间接效应0.93 [95%CI 0.87, 0.99])对2型糖尿病存在间接效应,中介比例分别为8%和5%;通过甘氨酸(间接效应0.98 [95%CI 0.96, 1.00])对冠状动脉疾病存在间接效应,中介比例为2%。
- 结果在至少一个独立数据集中得到良好验证。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the causal role of choline metabolites mediating sodium-glucose cotransporter 2 (SGLT2) inhibition in coronary artery disease (CAD) and type 2 diabetes (T2D) using Mendelian randomization (MR). RESEARCH DESIGN AND METHODS: A two-sample two-step MR was used to determine 1) causal effects of SGLT2 inhibition on CAD and T2D; 2) causal effects of three choline metabolites, total choline, phosphatidylcholine, and glycine, on CAD and T2D; and 3) mediation effects of these metabolites. Genetic proxies for SGLT2 inhibition were identified as variants in the SLC5A2 gene that were associated with both levels of gene expression and hemoglobin A1c. Summary statistics for metabolites were from UK Biobank, CAD from CARDIoGRAMplusC4D (Coronary ARtery DIsease Genome wide Replication and Meta-analysis [CARDIoGRAM] plus The Coronary Artery Disease [C4D] Genetics) consortium, and T2D from DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) and the FinnGen study. RESULTS: SGLT2 inhibition (per 1 SD, 6.75 mmol/mol [1.09%] lowering of HbA1c) was associated with lower risk of T2D and CAD (odds ratio [OR] 0.25 [95% CI 0.12, 0.54], and 0.51 [0.28, 0.94], respectively) and positively with total choline (β 0.39 [95% CI 0.06, 0.72]), phosphatidylcholine (0.40 [0.13, 0.67]), and glycine (0.34 [0.05, 0.63]). Total choline (OR 0.78 [95% CI 0.68, 0.89]) and phosphatidylcholine (OR 0.81 [0.72, 0.91]) were associated with T2D but not with CAD, while glycine was associated with CAD (0.94 [0.91, 0.98]) but not with T2D. Mediation analysis showed evidence of indirect effect of SGLT2 inhibition on T2D through total choline (0.91 [0.83, 0.99]) and phosphatidylcholine (0.93 [0.87, 0.99]) with a mediated proportion of 8% and 5% of the total effect, respectively, and on CAD through glycine (0.98 [0.96, 1.00]) with a mediated proportion of 2%. The results were well validated in at least one independent data set. CONCLUSIONS: Our study identified the causal roles of SGLT2 inhibition in choline metabolites. SGLT2 inhibition may influence T2D and CAD through different choline metabolites.
引用
- Xu M, Zheng J, Hou T, et al. SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study. Diabetes Care. 2022. PMID: 36161993. doi:10.2337/dc22-0323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。